國家衛生研究院 NHRI:Item 3990099045/14962
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 912861      在线人数 : 1189
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14962


    题名: Using precise boron neutron capture therapy as a salvage treatment for pediatric patients with recurrent brain tumors
    作者: Chen, YW;Lan, TL;Lee, YY;Lin, KH;Liang, ML;Chen, HH;Pan, PS;Chang, FC;Wu, CC;Lin, SC;Kang, YM;Lee, JC;Liu, HM;Chen, KH;Chen, JK;Lin, CF;Kuo, YC;Hsu, SM;Huang, WS;Chou, FI
    贡献者: Institute of Biomedical Engineering and Nanomedicine
    摘要: Background: Boron neutron capture therapy (BNCT) is a precise targeted particle therapy. Its principal purpose is to specifically administer boron-10-containing drugs to tumor cells and subsequently irradiate them with thermal neutrons. This highly explosive tumor destruction method exclusively attacks tumor cells that uptake boron-10-containing drugs, while minimizing damage to the surrounding normal cells without drug uptake, thereby making it an ideal option for the precise treatment of pediatric patients with recurrent brain tumors. Methods: Since March 2017, Taipei Veterans General Hospital collaborated with the Nuclear Science and Technology Development Center of National Tsing-Hua University to develop a salvage BNCT for recurrent tumors in the central nervous system. BNCT was delivered to patients using the research reactor of Tsing-Hua University. As of January 2020, a total of nine BNCT treatments (10 sites) have been performed on five pediatric patients with recurrent brain tumors. Results: The diagnoses of all five patients were recurrent glioblastomas, two of which developed from the brainstem. The median follow-up duration was 5.3 months. After BNCT, one site had complete response, and three had partial response. The median progression-free interval was 3.8 months. None of the five patients showed severe normal brain tissue necrosis nor serious complications after treatment. Conclusions: Pediatric patients are a vulnerable group with medical needs that are distinct from those of adult patients. BNCT is a precise cancer treatment for pediatric recurrent brain tumors with less normal toxicities and high tumor response.
    日期: 2020-12-30
    關聯: Therapeutic Radiology and Oncology. 2020 Dec 30;4:Article number 6521.
    Link to: http://dx.doi.org/10.21037/tro-20-20
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85129028197
    显示于类别:[陳仁焜] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    SCP85129028197.pdf643KbAdobe PDF94检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈